Clinical trial
An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders
NCT00308074 · Cambridge Health Alliance, Other · Completed
Key facts
| NCT number | NCT00308074 |
|---|---|
| Title | An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders |
| Official title | A Prospective Open-Label Trial of Aripiprazole Monotherapy in the Autism Spectrum Disorders (ASD) |
| Lead sponsor | Cambridge Health Alliance, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Autism, Asperger's Disorder, Pervasive Developmental Disorder |
| Intervention type | Drug |
| Interventions | Aripiprazole |
| Enrollment | 14 |
| Start date | Feb 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Feb 1, 2009 |
| First posted | Mar 29, 2006 |
| Last update posted | Feb 15, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: